Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation.
Identifieur interne : 001700 ( PubMed/Corpus ); précédent : 001699; suivant : 001701Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation.
Auteurs : C. Daubert ; P. Mabo ; D. Gras ; C. LeclercqSource :
- European heart journal [ 0195-668X ] ; 1993.
English descriptors
- KwdEn :
- Adrenergic beta-Antagonists (therapeutic use), Atrial Fibrillation (drug therapy), Atrial Flutter (drug therapy), Clinical Trials as Topic, Humans, Randomized Controlled Trials as Topic, Sotalol (chemistry), Sotalol (therapeutic use), Stereoisomerism, Tachycardia, Atrioventricular Nodal Reentry (drug therapy), Tachycardia, Supraventricular (drug therapy), Wolff-Parkinson-White Syndrome (drug therapy).
- MESH :
- chemical , chemistry : Sotalol.
- chemical , therapeutic use : Adrenergic beta-Antagonists, Sotalol.
- drug therapy : Atrial Fibrillation, Atrial Flutter, Tachycardia, Atrioventricular Nodal Reentry, Tachycardia, Supraventricular, Wolff-Parkinson-White Syndrome.
- Clinical Trials as Topic, Humans, Randomized Controlled Trials as Topic, Stereoisomerism.
Abstract
Numerous trials performed over the last 20 years, although uncontrolled, have shown the racemic d,l-sotalol is effective for the acute conversion and for long-term prevention of recurrences of supraventricular tachyarrhythmias. Sotalol appeared to be moderately effective in atrial fibrillation or atrial flutter, having somewhat greater efficacy in the case of atrioventricular (AV) nodal re-entrant tachycardia due to Wolff-Parkinson-White syndrome or concealed accessory pathway. These effects may stem from the combined class II and class III electrophysiologic properties of this drug. However, studies comparing d,l-sotalol to pure beta blockers in different 'models', especially postsurgical arrhythmias and Wolff-Parkinson-White syndrome, have suggested that the observed clinical benefit may be related to d,l-sotalol's class III properties. Thus, d-sotalol may be efficacious in these indications. Its precise efficacy should be defined in controlled clinical trials.
PubMed: 7904939
Links to Exploration step
pubmed:7904939Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation.</title><author><name sortKey="Daubert, C" sort="Daubert, C" uniqKey="Daubert C" first="C" last="Daubert">C. Daubert</name><affiliation><nlm:affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mabo, P" sort="Mabo, P" uniqKey="Mabo P" first="P" last="Mabo">P. Mabo</name></author><author><name sortKey="Gras, D" sort="Gras, D" uniqKey="Gras D" first="D" last="Gras">D. Gras</name></author><author><name sortKey="Leclercq, C" sort="Leclercq, C" uniqKey="Leclercq C" first="C" last="Leclercq">C. Leclercq</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1993">1993</date><idno type="RBID">pubmed:7904939</idno><idno type="pmid">7904939</idno><idno type="wicri:Area/PubMed/Corpus">001700</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001700</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation.</title><author><name sortKey="Daubert, C" sort="Daubert, C" uniqKey="Daubert C" first="C" last="Daubert">C. Daubert</name><affiliation><nlm:affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mabo, P" sort="Mabo, P" uniqKey="Mabo P" first="P" last="Mabo">P. Mabo</name></author><author><name sortKey="Gras, D" sort="Gras, D" uniqKey="Gras D" first="D" last="Gras">D. Gras</name></author><author><name sortKey="Leclercq, C" sort="Leclercq, C" uniqKey="Leclercq C" first="C" last="Leclercq">C. Leclercq</name></author></analytic><series><title level="j">European heart journal</title><idno type="ISSN">0195-668X</idno><imprint><date when="1993" type="published">1993</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic beta-Antagonists (therapeutic use)</term><term>Atrial Fibrillation (drug therapy)</term><term>Atrial Flutter (drug therapy)</term><term>Clinical Trials as Topic</term><term>Humans</term><term>Randomized Controlled Trials as Topic</term><term>Sotalol (chemistry)</term><term>Sotalol (therapeutic use)</term><term>Stereoisomerism</term><term>Tachycardia, Atrioventricular Nodal Reentry (drug therapy)</term><term>Tachycardia, Supraventricular (drug therapy)</term><term>Wolff-Parkinson-White Syndrome (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Sotalol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic beta-Antagonists</term><term>Sotalol</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Atrial Fibrillation</term><term>Atrial Flutter</term><term>Tachycardia, Atrioventricular Nodal Reentry</term><term>Tachycardia, Supraventricular</term><term>Wolff-Parkinson-White Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Humans</term><term>Randomized Controlled Trials as Topic</term><term>Stereoisomerism</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Numerous trials performed over the last 20 years, although uncontrolled, have shown the racemic d,l-sotalol is effective for the acute conversion and for long-term prevention of recurrences of supraventricular tachyarrhythmias. Sotalol appeared to be moderately effective in atrial fibrillation or atrial flutter, having somewhat greater efficacy in the case of atrioventricular (AV) nodal re-entrant tachycardia due to Wolff-Parkinson-White syndrome or concealed accessory pathway. These effects may stem from the combined class II and class III electrophysiologic properties of this drug. However, studies comparing d,l-sotalol to pure beta blockers in different 'models', especially postsurgical arrhythmias and Wolff-Parkinson-White syndrome, have suggested that the observed clinical benefit may be related to d,l-sotalol's class III properties. Thus, d-sotalol may be efficacious in these indications. Its precise efficacy should be defined in controlled clinical trials.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7904939</PMID><DateCreated><Year>1994</Year><Month>03</Month><Day>03</Day></DateCreated><DateCompleted><Year>1994</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0195-668X</ISSN><JournalIssue CitedMedium="Print"><Volume>14 Suppl H</Volume><PubDate><Year>1993</Year><Month>Nov</Month></PubDate></JournalIssue><Title>European heart journal</Title><ISOAbbreviation>Eur. Heart J.</ISOAbbreviation></Journal><ArticleTitle>Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation.</ArticleTitle><Pagination><MedlinePgn>67-73</MedlinePgn></Pagination><Abstract><AbstractText>Numerous trials performed over the last 20 years, although uncontrolled, have shown the racemic d,l-sotalol is effective for the acute conversion and for long-term prevention of recurrences of supraventricular tachyarrhythmias. Sotalol appeared to be moderately effective in atrial fibrillation or atrial flutter, having somewhat greater efficacy in the case of atrioventricular (AV) nodal re-entrant tachycardia due to Wolff-Parkinson-White syndrome or concealed accessory pathway. These effects may stem from the combined class II and class III electrophysiologic properties of this drug. However, studies comparing d,l-sotalol to pure beta blockers in different 'models', especially postsurgical arrhythmias and Wolff-Parkinson-White syndrome, have suggested that the observed clinical benefit may be related to d,l-sotalol's class III properties. Thus, d-sotalol may be efficacious in these indications. Its precise efficacy should be defined in controlled clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daubert</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service de Cardiologie, Hotel Dieu/Centre Hospitalier Regional et Universitaire, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mabo</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gras</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Leclercq</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J</MedlineTA><NlmUniqueID>8006263</NlmUniqueID><ISSNLinking>0195-668X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000319">Adrenergic beta-Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>A6D97U294I</RegistryNumber><NameOfSubstance UI="D013015">Sotalol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000319" MajorTopicYN="N">Adrenergic beta-Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="N">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001282" MajorTopicYN="N">Atrial Flutter</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013015" MajorTopicYN="N">Sotalol</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013237" MajorTopicYN="N">Stereoisomerism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013611" MajorTopicYN="N">Tachycardia, Atrioventricular Nodal Reentry</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013617" MajorTopicYN="N">Tachycardia, Supraventricular</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014927" MajorTopicYN="N">Wolff-Parkinson-White Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>37</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7904939</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001700 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001700 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:7904939
|texte= Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:7904939" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |